0098581
print

Prostate Specific Antigen, Ultrasensitive

PSA ULTRA
Example Reports
Abnormal
Normal

Ordering Recommendation

Use to monitor prostate cancer after radical prostatectomy. Do not use for initial prostate cancer screening; preferred test is Prostate Specific Antigen, Total (0070121) in conjunction with digital rectal exam.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum Separator Tube (SST). Also acceptable: Green (lithium heparin), Lavender (K2EDTA, or Pink (K2EDTA).

Specimen Preparation

Allow specimen to clot completely at room temperature. Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

Frozen.

Unacceptable Conditions

Grossly hemolyzed specimens. Vaginal washings.

Remarks
Stability

After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 6 months

Methodology

Quantitative Electrochemiluminescent Immunoassay

Performed

Sun-Sat

Reported

Within 24 hours

Reference Interval

0.00-4.00 ng/mL

Interpretive Data

After radical prostatectomy, the reference interval is less than 0.05 ng/mL if there is no residual disease. In healthy individuals without prostatectomy, the reference interval is 4.00 ng/mL or less. Lower limit of detection is 0.01 ng/mL.                                         

The Roche PSA electrochemiluminescent immunoassay is used. Results obtained with different test methods or kits cannot be used interchangeably. The Roche PSA method is approved for use as an aid in the detection of prostate cancer when used in conjunction with a digital rectal exam in individuals with a prostate 50 years and older. The Roche PSA is also indicated for the serial measurement of PSA to aid in the prognosis and management of prostate cancer patients. Elevated PSA concentrations can only suggest the presence of prostate cancer until biopsy is performed. PSA concentrations can also be elevated in benign prostatic hyperplasia or inflammatory conditions of the prostate. PSA is generally not elevated in healthy individuals or individuals with nonprostatic carcinoma. 

Compliance Category

FDA

Note

Hotline History

N/A

CPT Codes

84153

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
0098581 PSA, Ultrasensitive 35741-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Post Prostatectomy
  • PSA, Third Generation
  • Ultrasensitve PSA
Prostate Specific Antigen, Ultrasensitive